124935-88-2

Usage

Uses

Used in Pharmaceutical Industry:
2-[3-[Bis(1-methylethyl)amino]-1-phenyl-propyl]-4-methyl-methoxybenzene fumarate is used as an antihistamine medication for treating allergy symptoms such as sneezing, runny nose, and itching. It is effective due to its ability to block histamine action, reducing the discomfort associated with allergic reactions.
Used in Over-the-Counter Medications:
2-[3-[Bis(1-methylethyl)amino]-1-phenyl-propyl]-4-methyl-methoxybenzene fumarate is used as an over-the-counter medication, making it easily accessible for individuals seeking relief from mild to moderate allergy symptoms. Its safety and efficacy when used as directed make it a popular choice for self-treatment of allergies.
Used in Allergy Management:
2-[3-[Bis(1-methylethyl)amino]-1-phenyl-propyl]-4-methyl-methoxybenzene fumarate is used as a component in allergy management strategies to provide quick relief from allergic reactions. Its effectiveness in reducing histamine-induced symptoms makes it a valuable tool in managing allergic conditions.
Note: The chemical name provided is quite complex and is typically referred to by its trade name, Clemastine, in practical applications.

InChI:InChI=1/C23H33NO.C4H4O4/c1-6-25-22-14-10-13-21(17-22)23(20-11-8-7-9-12-20)15-16-24(18(2)3)19(4)5;5-3(6)1-2-4(7)8/h7-14,17-19,23H,6,15-16H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

Upstream product

• 882878-66-2 3-(2-methoxy-5-methylphenyl)-3-phenylpropyl-methanesulfonate 
• 108-18-9 diisopropylamine 
• 857288-56-3 N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropylamine hydrobromide 
• 854092-16-3 3-benzyl-4-methylanisole 
• 96-79-7 (2-chloroethyl)-diisopropylamine 
• 92197-18-7 N, N-diisopropyl-O-benzoyl hydroxylamine 
• 104-93-8 p-methylanizole 
• 4187-87-5 1-Phenyl-2-propyn-1-ol 
• 389068-20-6 1-methoxy-4-methyl-2-(1-phenyl-vinyl)-benzene 
• 934237-85-1 N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylprop-2-ene-1-amine 
• 109089-77-2 3-(2-methoxy-5-methyl-phenyl)-3-phenyl-propionic acid 
• 124937-85-5 toluene-4-sulfonic acid-3-(2-methoxy-5-methyl-phenyl)-3-phenyl propyl ester 

Downstream Products

• 837376-36-0 3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-aminium bromide 
• 857288-56-3 N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropylamine hydrobromide 
• 124936-74-9 N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine 
• 124937-51-5 (R)-(+)-tolterodine 
• 854306-72-2 bis{4-methyl-2-(3-phenylpropyl)phenol} 

Relevant academic research and scientific papers

Copper-catalysed selective hydroamination reactions of alkynes

The development of selective reactions that utilize easily available and abundant precursors for the efficient synthesis of amines is a long-standing goal of chemical research. Despite the centrality of amines in a number of important research areas, including medicinal chemistry, total synthesis and materials science, a general, selective and step-efficient synthesis of amines is still needed. Here, we describe a set of mild catalytic conditions utilizing a single copper-based catalyst that enables the direct preparation of three distinct and important amine classes (enamines, ±-chiral branched alkylamines and linear alkylamines) from readily available alkyne starting materials with high levels of chemo-, regio-and stereoselectivity. This methodology was applied to the asymmetric synthesis of rivastigmine and the formal synthesis of several other pharmaceutical agents, including duloxetine, atomoxetine, fluoxetine and tolterodine.

A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE

The present invention relates to provide an improved process for the preparation of tolterodine or salt thereof, comprises a step of reducing 3-(2-methoxy-5-methylphenyl) -3-phenyl propionic acid of formula (III) in the presence of a reducing agent, an acidic reagent and a solvent to obtain 3-(2-methoxy-5-methylphenyl) -3-phenyl propanol of formula (IV).

A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE

The present invention relates to provide a process for the preparation of (+)-(R)-Tolterodine-L-tartrate, comprises a step of aminating hydroxyl protected 3-(2-methoxy-5-methylphenyl)-3-phenyl propanol of formula (V) with diisopropylamine in the presence of water to obtain N, N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropyl amine of formula (VI).

METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES

The invention relates to a method of obtaining 3,3-diphenylpropylamines (I), wherein R1 is H, alkyl, haloalkyl or alkoxyalkyl, R2 is alkyl, alkoxy, halogen, NO2, CN, CHO, which may be free or protected, CH2OH or COOR6, and R3 and R4 are selected independently from H and alkyl or together with the nitrogen to which they are bound form a ring having 3 to 7 members. The inventive method consists in reacting a propylenephenylamine and a disubstituted aromatic hydrocarbon and, if necessary, separating the desired enantiomer or the mixture of enantiomers, and/or converting the compound (I) into a salt. Compounds (I) are muscarinic receptor antagonists which can be used in the treatment of urinary incontinence and other symptoms of urinary bladder hyperactivity. Said compounds include tolterodine.

Process for producing tolterodine

The present invention provides a process for producing tolterodine of the formula (1) or its salt, which comprises a step reacting a compound of the formula (2) with a base to obtain a reaction product; a step reacting the reaction product with a compound

NOVEL PROCESS FOR THE PREPARATION OF TOLTERODINE

The present invention relates to a novel and improved process for the preparation of tolterodine of formula I. Key steps involved in the process are a vinyl Grignard reaction on a benzophenone derivative of formula XXI to get the vinyl carbinol derivative

METHOD OF OBTAINING TOLTERODINE

The process comprises reacting a compound of formula (II), where R is a hydroxyl protecting group, and the asterisk indicates an asymmetric carbon atom, with diisopropylamine in the presence of a reducing agent; optionally converting the resulting intermediate into a salt and, if so desired, isolating it; removing the hydroxyl protecting group; and if so desired, separating the desired (R) or (S) enantiomer, or the mixture of enantiomers and/or converting the obtained compound into a pharmaceutically acceptable salt thereof. Tolterodine is a muscarinic receptor antagonist useful in treating urinary incontinence and other symptoms of urinary bladder hyperactivity.

Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propaneamine

A process is described for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propaneamine comprising substitution of the sulfonyloxy group of the compound of the formula in which the substituents R and R″ have the meanings stated in the description, in a solvent comprising an ionic liquid, to yield the tertiary amine of the formula and the subsequent deprotection thereof.

Process for the preparation of tolterodine

A novel process for the preparation of tolterodine, i.e. (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation.

A process for the preparation of tolterodine

A novel process for the preparation of tolterodine (I), i.e. (R)-N,N-diisopropyI-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation.